A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis

NCT ID: NCT02425852

Last Updated: 2023-05-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 65 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-12-31
• Study Completion Date: 2023-01-31

Brief Summary

PHASE : IV TYPE OF STUDY : With direct benefit. DESCRIPTIVE : Multicentre, randomized, open label study. INCLUSION CRITERIA : Acute severe ulcerative colitis. OBJECTIVES : To compare the efficacy and safety of early administration of the combination therapy with infliximab and azathioprine with steroids and azathioprine in patients with acute severe ulcerative colitis treated with intravenous steroids.

STUDY TREATMENTS : All patients :

Intravenous steroids (0.8 mg/kg/day of methylprednisolone or equivalent) for 5 days.

Combination therapy arm:

Infliximab 5 mg/kg plus Azathioprine 2-2.5 mg/kg/day.

Azathioprine arm:

Steroids tapering for 3 months and Azathioprine 2-2.5 mg/kg/day.

Detailed Description

NUMBER OF PATIENTS : 73 patients in each group i.e. a total of 146patients. RECRUITMENT PERIOD : 36 months STUDY DURATION : 12 months

PRIMARY END POINT : Treatment failure is defined by:

• Absence of steroid-free remission at W52 according to the total Mayo Disease Activity Index score
• OR Absence of mucosal healing (Mayo endoscopic subscore 0-1)
• OR Adverse event leading to treatment interruption
• OR Colectomy
• OR Death
• OR Infliximab withdrawal in the combination therapy group OR Infliximab introduction in the azathioprine group SECONDARY END POINT: - Clinical response and remission at D7, W14 and W52 (according to Lichtiger score and total Mayo Disease Activity Index score)
• Endoscopic and histological response
• Mucosal healing (partial endoscopic Mayo subscore 0)
• Colectomy rate
• Adverse events rate
• Fecal calprotectin
• Health-economic outcome

Conditions

Ulcerative Colitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Combination therapy arm

Infliximab 5 mg/kg plus Azathioprine 2-2.5 mg/kg/day. Azathioprine will be introduced at day 5-7 and continued until week 52. Azathioprine dose regimen will be between 2 and 2.5 mg/kg/d, as close as possible to 2.5 mg/kg/d, or to 1.5 mg/kg/d for 6-mercaptopurine, in one daily intake.

Group Type: ACTIVE_COMPARATOR

Azathioprine

Intervention Type: DRUG

Azathioprine alone versus Azathioprine and IFX

Infliximab

Intervention Type: DRUG

Azathioprine arm

Intravenous steroids will be continue until day 2. Then, steroid therapy will be orally administered at a dose of 40-60 mg/day ou 1 mg/kg/day prednisolone (or equivalent) and progressively reduced by 10mg step every week to 20mg per day, and then reduced by 5mg step every week until stopped. Hydrocortisone intake to prevent steroid weaning will be authorized until supradrenal function normalization.

In patients with clinical response at day 7, Azathioprine will be introduced at day 5-7 and continued until week 52. Azathioprine dose regimen will be between 2 and 2.5 mg/kg/d, as close as possible of 2.5 mg/kg/d, or of 1.5 mg/kg/d for 6-mercaptopurine, in one daily intake.

Group Type: ACTIVE_COMPARATOR

Azathioprine

Intervention Type: DRUG

Azathioprine alone versus Azathioprine and IFX

Prednisolone

Intervention Type: DRUG

Hydrocortisone

Intervention Type: DRUG

Interventions

Azathioprine

Azathioprine alone versus Azathioprine and IFX

Intervention Type: DRUG

Infliximab

Intervention Type: DRUG

Prednisolone

Intervention Type: DRUG

Hydrocortisone

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age > 18 years.
• Diagnosis of UC according to Lennard-Jones criteria (Appendix 1).
• Endoscopically demonstrated colorectal lesions localized above the anal margin and extending at least up to 15cm proximally (Endoscopic Mayo subscore ≥ 2).
• Acute flare requiring hospitalization
• Severe acute flare of UC with a Lichtiger Index score > 10 at Day -3
• Adequate contraception for male or female subjects of childbearing potential, which will be continued throughout the study and at least 3 months after study termination.

Exclusion Criteria

• Pregnant or breast-feeding woman.
• Previous treatment with infliximab.
• Treatment with adalimumab or golimumab within 8 weeks before randomization
• Treatment with vedolizumab within 4 weeks before randomization
• Azathioprine or 6-mercaptopurine treatment initiated more than 4 weeks before screening.
• Ongoing intravenous steroids for more than 96 hours at time of the screening
• Contraindication for anti-TNF therapy
• Indication for immediate surgery.
• History of colorectal dysplasia.
• Diagnosis of Crohn's disease or indeterminate colitis
• Positive stool tests for amoebiasis and/or positive bacteriological culture for Salmonella, Shigella, Yersinia and Campylobacter and/or presence of Clostridium difficile B toxin in the stools.
• Renal failure (creatininemia > upper limit of normal laboratory value).
• Uncontrolled high blood pressure.
• HIV, HBV viral infection (except the presence of positive anti-HBs antibodies) with serology not older than 3 months.
• Uncontrolled bacterial or active viral infection.
• Past medical history of malignant condition in the last 5 years (including leukaemia, lymphoma and myelodysplasia) except for baso-cellular cutaneous cancers.
• Past medical history of myocardial infarction or heart failure.
• Intradermal reaction to Tuberculin (Tubertest® 5 units) > 5mm or positive interferon-gamma release assay (Quantiferon®)
• Active tuberculosis
• Untreated latent tuberculosis (see national recommendations. Appendix 2).
• Abnormal blood count with polynuclear neutrophils < 1,500 G/L or white cells < 3,000, or platelets < 100,000 G/L.
• Unexplained rise higher than 3 times the normal level for transaminases, alkaline phosphatases and/or higher than twice the normal level for bilirubin.
• Severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in judgement of the investigator, would make the subject inappropriate for entry in this study.
• Subjects who, in the opinion of the investigator, will be uncooperative or unable to comply with study procedures.
• Participation in another clinical trial.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Aurélien Amiot, MD

Role: PRINCIPAL_INVESTIGATOR

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

Laurent Peyrin-Biroulet, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

Locations

Chu Besancon

Besançon, , France

CHU de CLERMONT FERRAND- Hopital Estain

Clermont-Ferrand, , France

APHP- Hopital BEAUJON

Clichy, , France

Hopital Louis Mourrier

Colombes, , France

Henri Mondor Hospital

Créteil, , France

Chu Kremlin Bicetre

Le Kremlin-Bicêtre, , France

CHRU Lille

Lille, , France

Chu Montpellier

Montpellier, , France

CHU de NICE- Hopital Archet 2

Nice, , France

Hopital Saint Louis

Paris, , France

Hopital St Antoine

Paris, , France

Hopital Saint Joseph

Paris, , France

CHU RENNES - Hopital Pontchaillou

Rennes, , France

Chu Rouen

Rouen, , France

Chu Saint Etienne

Saint-Etienne, , France

CHU NANCY - Hopital Brabois

Vandœuvre-lès-Nancy, , France

Countries

France

References

Amiot A, Seksik P, Meyer A, Stefanescu C, Wils P, Altwegg R, Vuitton L, Plastaras L, Nicolau A, Pereira B, Duveau N, Laharie D, Mboup B, Boualit M, Allez M, Rajca S, Chanteloup E, Bouguen G, Bazin T, Goutorbe F, Richard N, Moussata D, Vicaut E, Peyrin-Biroulet L. Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trial. Gut. 2025 Jan 17;74(2):197-205. doi: 10.1136/gutjnl-2024-333281.

Reference Type: DERIVED

PMID: 39586616 (View on PubMed)

Other Identifiers

GETAID 2015-02

Identifier Type: -

Identifier Source: org_study_id